Atopic Dermatitis Market
Atopic Dermatitis Market

Atopic Dermatitis (AD), also known as atopic eczema, is a type of skin inflammation (dermatitis). It results in itchy, red, swollen, and cracked skin.

Some of Atopic Dermatitis Facts:

  • No cure has been found for Atopic Dermatitis yet.
  • Atopic Dermatitis is common in children but can occur at any age.
  • Atopic Dermatitis most often begins before the age of 5 and may persist into adolescence and adulthood.
  • Itching is the hallmark of  Atopic Dermatitis, more than 85% of people have experienced the condition.
  • Currently, there is no reliable biomarker to distinguish the disease from other entities.

Atopic Dermatitis Epidemiology Segmentation

  • Atopic Dermatitis Prevalent Population  
  • Atopic Dermatitis  Diagnosed Prevalent Population
  • Severity-specific Distribution in Adults
  • Severity-specific Distribution in Pediatric Population
  • Gender-specific Distribution in Adults
  • Chronic Pruritus Prevalence in the adults


Atopic Dermatitis Epidemiological Insights Observed in 2020

  • The total diagnosed prevalent population of Atopic Dermatitis in the 7MM was observed to be 52,941,993.
  • The diagnosed Atopic Dermatitis prevalent population in the United States was found to be 24,039,022 in 2020.
  • The diagnosed Atopic Dermatitis prevalent population in Japan was found to be 6,969,898 in 2020.
  • Among the EU5 countries, the United Kingdom had the highest Atopic Dermatitis incident cases whereas Spain had the lowest incident cases of Atopic Dermatitis in 2020.

Atopic Dermatitis Market Insight

Atopic Dermatitis market size in the 7MM was found to be USD 14,172 Million in 2020.  

Atopic Dermatitis Market Drivers

  • Rising prevalence
  • Escalating expenditure on health care
  • Approvals of JAK inhibitors
  • Potential emerging therapies for AD and Pruritus
  • Increasing awareness

Atopic Dermatitis Market Barriers

  • Over-the-counter medications
  • Outdated treatment recommendations
  • Poor prognosis and treatment adherence
  • Lack of timely diagnosis
  • Management of AD in the primary care setting

Atopic Dermatitis Emerging Drugs

The emerging drugs of the Atopic Dermatitis market are

  • Ly3650150
  • Etrasimod
  • FB825
  • Nemolizumab
  • Difamilast
  • DS107
  • Bermekimab
  • B244
  • KY1005 (Amlitelimab)
  • Q301
  • Roflumilast
  • Difelikefalin (Korsuva)
  • Tradipitant, and several others 

Atopic Dermatitis Companies

The key players working in the Atopic Dermatitis market are

  • Eli Lilly and Company
  • Arena Pharmaceuticals
  • Oneness Biotech
  • Galderma
  • Otsuka Pharmaceutical
  • DS Biopharma
  • Janssen
  • AOBiome Therapeutics
  • Sanofi/Kymab
  • Qurient
  • Arcutis Biotherapeutics
  • Cara Therapeutics
  • Vanda Pharmaceutical, and several others